Introduction
============

Left atrium (LA) dilation has been associated with adverse cardiovascular outcomes in patients with sinus rhythm \[[@B1]-[@B5]\]. Among patients with atrial fibrillation (AF), LA enlargement has been suggested as predictor of stroke in some studies \[[@B6]-[@B11]\], while others have shown conflicting results \[[@B12]\].

Most investigations regarding the prognostic impact of LA size relied on the antero-posterior diameter measured by M-mode (LA AP diameter). However, this method is based in several geometric assumptions that often result in LA size underestimation \[[@B11]-[@B16]\]. Thus, LA areas and volumes derived from two-dimensional transthoracic echocardiography (TTE) seem to provide a more accurate assessment of LA size \[[@B17]-[@B19]\].

Transesophageal echocardiography (TEE) allows the assessment of parameters associated with stroke, thromboembolism and adverse prognosis, notably the presence of thrombus in the LA appendage (LAA thrombus) \[[@B20]\], spontaneous echocardiographic contrast (SEC) \[[@B20],[@B21]\], low LA appendage flow velocities (low LAA velocities) \[[@B22]-[@B25]\]. The best method to assess the relationship between LA size and the aforementioned LA abnormalities on TEE has never been evaluated.

This study aims to evaluate the accuracy of LA size to identify surrogate TEE markers of an increased risk of stroke (LAA thrombus, low LAA velocities and dense SEC), and also to assess the best method to evaluate LA size in this setting.

Methods
=======

Study design
------------

Cross-sectional study enrolling patients undergoing TTE and TEE during a non-valvular AF episode. LA size was measured on TTE by several methods (LA AP diameter, LA area and LA volumes). Surrogate markers of stroke were evaluated by TEE: LAA thrombus, low LAA velocities, dense SEC, and LA ABN. ROC curve analysis was performed to assess the accuracy of the different LA measurements to identify surrogate markers of stroke. All patients provided informed consent for echocardiographic evaluation. The study protocol was approved by *Comissão de Ética da Faculdade de Medicina da Universidade de Coimbra* (Ref 5/2013 ).

Patients and eligibility criteria
---------------------------------

Five hundred consecutive adult patients undergoing TTE and TEE during symptomatic episode of non-valvular AF were enrolled during a 36-month period. AF was identified by an electrocardiogram or endocardial electrograms (in patients with pacemakers or implantable cardioverter defibrillators). Exclusion criteria were moderate or severe mitral stenosis, severe mitral regurgitation, severe aortic stenosis prosthetic mitral or aortic valves, patients with unsuitable images for accurate assessment of TTE measurements or TEE surrogate markers of stroke, or any contraindication to TEE. Most patients had an echocardiogram performed as part of evaluation before electrical cardioversion (n = 466, 93.2%); in the remaining patients, it was conducted for mitral valve disease assessment (n = 14; 2.8%) and stroke evaluation (n = 20; 4%).

Initial data collection
-----------------------

Demographic, anthropometric, clinical, laboratory, additional echocardiographic and medication data were retrieved from clinical records (outpatient clinic evaluations, emergency department, and hospital-ward admissions). Discharge primary and secondary diagnoses were recorded according to the ICD-10 (international classification of diseases, 10th revision). Duration of AF episode was estimated according to the patients' complaints, previously available clinical records and ECG. In patients with pacemakers and implantable cardioverter defibrillators device interrogation was performed in order to estimate the duration of the episode. The CHADS~2~\[[@B26]\] and CHA~2~DS~2~-VASc \[[@B27]\] scores, glomerular filtration rate (MDRD formula), body mass index and body surface area were calculated for all participants. Laboratory tests were performed within 24 hours of hospital admission for patients undergoing TEE in the emergency department and in the month preceding the transesophageal echocardiographic examination for participants undergoing elective TEE. Patients were thought to have congestive heart failure whenever concordant signs or symptoms were registered in their medical records. Vascular disease was defined by the presence of at least one of the following: previous myocardial infarction, peripheral artery disease or complex aortic plaque.

Echocardiographic data acquisition
----------------------------------

All patients underwent a comprehensive imaging and Doppler echocardiographic examination using a commercially available system (Vivid 7 Dimension, GE Healthcare, Horten, Norway) according to our laboratory protocol. Examinations were performed by three trained transthoracic and transoesophageal echocardiographers, the images were stored on digital media for subsequent analysis using the commercially available software EchoPac Dimension PC version 108.1.4, GE Health Care, and were reviewed by two investigators.

M-mode and two-dimensional transthoracic images were acquired using a M4S probe (1.5--4.0 MHz), and were used to obtain the following LA measurements: LA AP diameter, LA area from 4-chamber view (4C), and LA volumes by the ellipsoid, single plane (1P) area-length and biplane (2P) area-length methods. These measurements were obtained at end-ventricular systole, from the frame immediately preceding mitral valve opening, as shown in Figure [1](#F1){ref-type="fig"}. LA AP diameter (D1) was measured by M-mode from the parasternal long-axis view. LA area was measured using planimetry in TTE apical four-chamber and two chamber view. LA ellipsoid volume was calculated using AP (D1), medial--lateral (D2) and superior--inferior (D3) LA diameters (Figure [1](#F1){ref-type="fig"}) and the formula: 4/3π\*(D1/2) \* (D2/2) \* (D3/2). LA 1P area-length volume was obtained through the formula 8/3π\*A1^2^/D3, where A1 represents the area and D3 the superior-inferior LA diameter measured from apical 4C view. LA 2P area-length volume was achieved with the formula 8/3 π\*\[(A1) \* (A2)/L\], where A2 represent the LA area 2-chamber (2C) view, and L the shortest superior-inferior diameter measured in 4C (D3) and 2C (D4) views (Figure [1](#F1){ref-type="fig"}). All these measurements were indexed to body surface area.

![**Echocardiographic parameters used to calculate the left atrial volumes.** Legend: A1 - LA area in 4C view; A2 - LA area in 2C view; D1 - LA AP diameter; D2 - medial--lateral diameter; D3 - superior-inferior diameter in 4C view; D4 - superior-inferior diameter in 2C view.](1476-7120-12-28-1){#F1}

TEE images were acquired with a 6 T phased array multiplane transoesophageal probe (2.9--7.0 MHz). The LA and LAA were imaged in different tomographic planes to detect the presence of LAA thrombus and SEC. LA thrombus was diagnosed by the presence of an echo-dense mass in the left atrium or the LAA \[[@B28]\]. Spontaneous echocardiographic contrast was diagnosed by the presence of characteristic dynamic smoke-like swirling echoes in the LA or the LAA, distinct from background white noise caused by excessive gain \[[@B29]\], and was classified according to the classification (1 to 4+) proposed by Fatkin et al. \[[@B30]\]. Dense SEC was defined as grade 3+ or 4+. Left atrial appendage flow velocities were assessed with a pulsed Doppler sample placed 1 cm from the entry of the LAA into the body of the LA. Maximum emptying and filling velocities were estimated from an average of five well-defined emptying and filling waves. Patients with maximum emptying and filling velocity ≤20 cm/s were classified as having low flow velocities.

Study endpoints
---------------

The study endpoints were the TEE surrogate markers of stroke: LAA thrombus, LAA low flow velocities and dense SEC. The composite endpoint of LA abnormality (LA ABN) was defined by the presence of at least one of the previous markers.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS, version 17.0. Baseline characteristics were described with mean ± standard deviation for continuous data and counts and proportions for categorical data. The Kolmogorov-Smirnov test was used to test the normal distribution of continuous variables. The Chi-square test, Student's *t*-test and non-parametric equivalent tests were used when appropriate. P values \<0.05 (two-sided) were considered statistically significant.

A comparative univariate analysis of patients with and without LA ABN was performed to evaluate potential differences between the groups regarding demographic, clinical, echocardiographic and laboratorial parameters.

The discriminatory power of the indexed and non-indexed LA measurements (AP diameter, area 4C, ellipsoid volume, 1P area-length volume and 2P area-length volume) to identify TEE surrogate markers of stroke (LAA thrombus, LAA low flow velocities, dense SEC and LA ABN) was evaluated through the receiver operating characteristic (ROC) curve, which refers to the ability of a model to assign a higher probability to patients reaching an endpoint than those who did not reach it. Comparisons of areas under ROC curves (AUC) were performed between LA indexed measurements, using MedCalc for Windows version 9.2.0.1. A ROC curve subanalysis was also carried out for patients previously under oral anticoagulation regarding LA thrombus, LAA low flow velocities or at least one of these two parameters.

Finally, multivariate analysis (forward conditional method) was performed to identify independent predictors of TEE surrogate markers of stroke, among the different methods of LA size quantification and the parameters included in CHADS~2~ or CHA~2~DS~2~-VASc scores.

Inter- and intra-observer variability was assessed for the three echocardiographers using a sample composed of the first 50 patients included in the study: for dense SEC and LAA thrombus correlations were used; for LA measurements, we performed a Bland-Altman analysis using MedCalc for Windows version 9.2.0.1.

Results
=======

Study population
----------------

Baseline characteristics of the 500 patients enrolled in this study are summarized in Table [1](#T1){ref-type="table"}. There was a lower prevalence of female gender (34.2%). The average CHADS~2~ and CHA~2~DS~2~-VASc scores were 1.9 ± 1.2 and 3.2 ± 1.7, respectively. Forty point six per cent of patients were previously medicated with oral anticoagulants and 33.8% with antiplatelet agents; in 33.8% of patients, one to three injections of enoxaparin were performed prior to TEE. The duration of the current atrial fibrillation episode was estimated to be longer than one year in 26.8% of patients (Table [1](#T1){ref-type="table"}). AF was persistent in 73.2% of patients (n = 366) and long-standing persistent in 26.8% of patients (n = 134). TEE examinations identified 55 patients (11.1%) with LAA thrombus, 66 (13.2%) with low LAA flow velocities and 120 (24%) with dense SEC. LA ABN was present in 29.6% of patients (n = 148).

###### 

Study population baseline characteristics

    **Baseline characteristics (n = 500)**                                                                              
  ------------------------------------------- -------------------------------- ---------------------------------------- --------------
               **Demographics**                **Medication previous to TEE**                                           
                  Age (years)                             69 ± 10                        Oral Anticoagulation            40.6% (203)
                Age ≥ 75 years                           31% (155)                       Antiplatelet agents             46.4% (232)
               Age 65--74 years                         39.8% (199)                    1-3 doses of enoxaparine          33.8% (169)
           Body Mass Index (Kg/m^2^)                     26.6 ± 8.8             **Echocardiographic characterization**  
                 Female gender                          34.2% (171)                      LA AP diameter (cm)              4.7 ± 0.7
               **Clinical data**                      LA area (cm^2^)                         27.6 ± 7.1                
                 Hypertension                           81.8% (409)                  LA ellipsoid volume (cm^3^)         74.1 ± 29.0
                   Diabetes                             23.6% (118)                LA 1P area-length volume (cm^3^)      113.8 ± 47.7
              Previous Stroke/TIA                        14.8% (74)                LA 2P area-length volume (cm^3^)      104.1 ± 38.1
           Congestive heart failure                     54.8% (274)                   LV ejection fraction ≥55%          73.6% (368)
              Vascular disease^a^                        52% (260)                           LAA thrombus                 11.1% (55)
                   CHADS~2~                              1.9 ± 1.2                     LAA low flow velocities            13.2% (66)
               CHA~2~DS~2~-VASc                          3.2 ± 1.7                            Dense SEC                   24% (120)
               Pacemaker or ICD                          19.6% (98)                             LA ABN                   29.6% (148)
   **Estimated current AF episode duration**    **Laboratorial evaluation**                                             
                  ≤ 48 hours                              7% (35)                         Haemoglobin (g/dL)              13.2 ± 1.8
                   \< 1 week                             19.6% (98)                      Platelets (10^3^/μL)            219.7 ± 85.5
                  \< 1 month                             36% (180)                               INR                      1.5 ± 0.8
                  \> 6 months                           35.8% (179)                           INR ≥ 2.0                  20.8% (104)
                   \> 1 year                            26.8% (134)                     GFR (mL/min/1.73 m^2^)           62.4 ± 33.0

Legend: GFR -- glomerular filtration rate; ICD - implantable cardioverter defibrillator; INR -- international normalized ratio; LV -- left ventricle; TIA -- transient ischaemic attack.

^a^Vascular disease is defined as having at least one of the following: myocardial infarctions, peripheral artery disease, and complex aortic plaque.

The sub-analysis of demographic, clinical, echocardiographic and laboratorial characteristics of the study population according to the presence or absence of LA ABN is presented in Table [2](#T2){ref-type="table"}. Patients with LA ABN had higher thromboembolic risk (CHADS~2~: 2.1 ± 1.1 vs. 1.8 ± 1.2, p = 0.001; CHA~2~DS~2~-VASc: 3.6 ± 1.6 vs. 3.0 ± 1.7, p \< 0.001), were older (70 ± 8 vs. 68 ± 11, p = 0.02), had higher prevalence of congestive heart failure (65.7% vs. 50.4%, p = 0.002) and vascular disease (62.8% vs. 47.4%, p = 0.003), and less frequently a left ventricle ejection fraction ≥55% (58.8% vs. 79.8%, p \< 0.001). They presented higher values for all LA measurements performed and had longer AF duration (Table [2](#T2){ref-type="table"}). Although patients with LA ABN were more often anticoagulated (50% vs. 36.6%, p = 0.01), there was no difference in the prevalence of effective anticoagulation (20.9% vs. 20.7%, p = ns) or in the average INR (1.5 ± 0.7 vs. 1.5 ± 0.8, p = ns) at the time TEE was performed.

###### 

Sub-analysis of baseline characteristics according to the presence of left atrial abnormality

                   **Parameter**                   **Without LA ABN**   **With LA ABN**    **p**
  ----------------------------------------------- -------------------- ----------------- ---------
                 **Demographics**                                                        
                    Age (years)                         68 ± 11             70 ± 8         0.02
             Body Mass Index (Kg/m^2^)                  26.8 ± 9           26 ± 8.1         0.4
                   Female gender                       33% (116)          37.2% (55)        0.4
                 **Clinical data**                                                       
                   Hypertension                       80.8% (284)         84.6% (125)       0.4
                     Diabetes                          21.9% (77)          28% (41)         0.1
                Previous Stroke/TIA                    13.2% (46)         18.9% (28)        0.1
             Congestive heart failure                 50.4% (177)         65.7% (97)       0.002
                Vascular disease^a^                   47.4% (167)         62.8% (93)       0.003
                  CHADS~2~ score                       1.8 ± 1.2           2.1 ± 1.1       0.001
              CHA~2~DS~2~-VASc score                    3 ± 1.7            3.6 ± 1.6      \<0.001
                 Pacemaker or ICD                      18.8% (66)         21.7% (32)        0.7
     **Estimated current AF episode duration**                                           
                    ≤ 48 hours                         8.5% (30)           3.6% (5)        0.06
                     \< 1 week                          24% (84)           9.5% (14)      \<0.001
                    \< 1 month                         40% (141)          26.3% (39)       0.001
                    \> 6 months                        31% (109)          47.3% (70)       0.001
                     \> 1 year                         22.2% (78)         37.8% (51)       0.001
      **Echocardiographic characterization**                                             
               LA AP diameter, (cm)                    4.6 ± 0.7           4.8 ± 0.8       0.004
                  LA area (cm^2^)                      26.4 ± 6.8         30.3 ± 7.1      \<0.001
            LA ellipsoid volume (cm^3^)               70.5 ± 28.2         82.1 ± 29.4      0.001
         LA 1P area-length volume (cm^3^)             106.6 ± 45.9        130 ± 47.7      \<0.001
         LA 2P area-length volume (cm^3^)             97.6 ± 37.6         117 ± 35.9      \<0.001
         Indexed LA AP diameter, (cm/m^2^)             2.4 ± 0.5           2.7 ± 0.4      \<0.001
           Indexed LA area (cm^2^/m^2^)                14.2 ± 4.1         16.9 ± 4.1      \<0.001
     Indexed LA ellipsoid volume (cm^3^/m^2^)         37.6 ± 16.3         45.3 ± 16.3     \<0.001
   Indexed LA 1P area-length volume (cm^3^/m^2^)      56.9 ± 24.7         72.3 ± 26.9     \<0.001
   Indexed LA 2P area-length volume (cm^3^/m^2^)      51.9 ± 20.6         64.8 ± 20.9     \<0.001
             LV ejection fraction ≥55%                79.8% (281)         58.8% (87)      \<0.001
          **Medication previous to TEE**                                                 
               Oral Antiocagulation                   36.6% (129)          50% (74)        0.01
                Antiplatelet agents                   48.8% (172)         40.5% (60)        0.1
             1-3 doses of enoxaparine                 36.1% (127)         28.3% (42)        0.1
            **Laboratorial evaluation**                                                  
                Haemoglobin (g/dL)                     13.3 ± 1.9         13.1 ± 1.6        0.3
               Platelets (10^3^/μL)                   220.6 ± 91.4       217.5 ± 69.4       0.7
                        INR                            1.5 ± 0.8           1.5 ± 0.7        0.8
                     INR ≥ 2.0                         20.7% (73)         20.9% (31)       0.96
              GFR (mL/min/1.73 m^2^)                  61.9 ± 33.1         63.8 ± 32.8       0.6

Legend: GFR -- glomerular filtration rate; ICD - implantable cardioverter defibrillator; INR -- international normalized ratio; LV -- left ventricle; TIA -- transient ischaemic attack.

^a^Vascular disease is defined as having at least one of the following: myocardial infarctions, peripheral artery disease, and complex aortic plaque.

LA measurements for identifying surrogate markers of stroke on TEE
------------------------------------------------------------------

Figure [2](#F2){ref-type="fig"} presents the results of ROC curve analysis of the different indexed and non-indexed LA measurements for identifying LAA thrombus, LAA low flow velocities, dense SEC and LA ABN.Except for LA AP diameter in identifying LA thrombus, all other LA measurements showed a good discriminatory ability in the prediction of the study endpoints (Figure [2](#F2){ref-type="fig"}). Indexing to body surface area increased the accuracy of every LA measurement to recognize each TEE surrogate marker of stroke (Figure [2](#F2){ref-type="fig"}).Taking into account the possible influence of oral anticoagulation on dense SEC, a sub-analysis of the discriminatory ability of LA measurements for predicting the other surrogate markers of stroke (LA thrombus, LAA low flow velocities or at least one of these two parameters), was carried out for patients previously under oral anticoagulation (Figure [3](#F3){ref-type="fig"}). In this subset of 165 patients, LAA thrombus was found in 21 patients, LAA low flow velocities in 23 patients and at least one of these parameters in 40 patients. There was a good discriminatory ability of the LA measurements for identifying LAA low flow velocities in this sample, though the results were not as consistent for identifying LAA thrombus (Figure [3](#F3){ref-type="fig"}).

![**Receiver operating characteristic-curve analysis of indexed and non-indexed left atrial measurements for identifying TEE endpoints.** Legend: AP -- anteroposterior; AUC -- area under the curve; CI -- confidence interval; LA -- left atrial; LAA -- left atrial appendage; LA ABN -- left atrial abnormality; p -- significance level; SEC -- spontaneous echocardiographic contrast; 4C -- 4-chamber; 1P -- single-plane; 2P -- biplane.](1476-7120-12-28-2){#F2}

![**Receiver operating characteristic-curve sub-analysis of left atrial measurements for identifying LAA thrombus, LAA low flow velocities or at least one of one of these parameters, in patients under previous oral anticoagulation.** Legend: AP -- anteroposterior; AUC -- area under the curve; CI -- confidence interval; LA -- left atrial; LAA -- left atrial appendage; p -- significance level; 4C -- 4-chamber; 1P -- single-plane; 2P -- biplane.](1476-7120-12-28-3){#F3}

The most suitable TTE measurements to identify TEE surrogate markers of stroke
------------------------------------------------------------------------------

The highest AUC for the prediction of study endpoints was achieved with indexed LA area 4C for LAA thrombus (AUC 0.788, CI~95%~ 0.644 -- 0.772, p \< 0.001), dense SEC (AUC 0.693, CI~95%~ 0.638 -- 0.748, p \< 0.001) and LA ABN (AUC 0.705, CI~95%~ 0.654 -- 0.755, p \< 0.001). Regarding LAA low flow velocities, the highest AUC was obtained with indexed 2P area-length method (AUC 0.737, CI~95%~ 0.664 -- 0.810, p \< 0.001) -- Figure [2](#F2){ref-type="fig"}.

Generally, indexed LA area 4C and indexed 1P and 2P area-length methods showed a moderately high discriminatory power in the prediction of the study endpoints and stood out from all the other measurements. ROC curve comparison for these three measurements did not reveal a significant difference between them (Table [3](#T3){ref-type="table"}).

###### 

Cross Tabulation of ROC AUC between the different indexed methods

   **Indexed LA AP diameter**          **Indexed LA Area 4C**          **Indexed LA elipsoid volume**    **Indexed LA 1P area-length volume**   **Indexed LA 2P area-length volume**
  ---------------------------- -------------------------------------- --------------------------------- -------------------------------------- --------------------------------------
   **Indexed LA AP diameter**              LAAT p = 0.08                       LAAT p = 0.910                       LAAT p = 0.122                         LAAT p = 0.082
          DSEC p = 0.1                     DSEC p = 0.231                      DSEC p = 0.248                       DSEC p = 0.389             
       **LFV p = 0.024**                   LFV p = 0.358                        LFV p = 0.127                       LFV p = 0.245              
                                        **LA ABN p = 0.046**                  LA ABN p = 0.187                     LA ABN p = 0.154                       LA ABN p = 0.249
                                       **Indexed LA Area 4C**                **LAAT p = 0.037**                     LAAT p = 0.888                         LAAT p = 0.795
         DSEC p = 0.451                    DSEC p = 0.466                      DSEC p = 0.358                                                  
         LFV p = 0.064                     LFV p = 0.061                        LFV p = 0.069                                                  
                                                                              LA ABN p = 0.212                     LA ABN p = 0.186                       LA ABN p = 0.242
                                                                       **Indexed LA elipsoide volume**            **LAAT p = 0.010**                     **LAAT p = 0.033**
         DSEC p = 0.722                    DSEC p = 0.997                                                                                      
         LFV p = 0.314                     LFV p = 0.472                                                                                       
        LA ABN p = 0.565                  LA ABN p = 0.805                                                                                     
                                                                                                         **Indexed LA 1P area-length volume**              LAAT p = 0.766
         DSEC p = 0.608                                                                                                                        
         LFV p = 0.519                                                                                                                         
        LA ABN p = 0.633                                                                                                                       
                                **Indexed LA 2P area-length volume**                                                                           

Legend: AP -- anteroposterior; DSEC -- dense spontaneous echocardiographic contrast; LA -- left atrial; LA ABN -- left atrial abnormality; LAAT -- left atrial appendage thrombus; LFV - left atrial appendage low flow velocities; p -- significance level; 4C -- 4-chamber; 1P -- single-plane; 2P -- biplane.

On multivariate analysis considering the different methods of LA size quantification and the parameters included in CHADS~2~ score, indexed LA area 4C was an independent predictor of LAA low flow velocities, dense SEC and LA ABN, while indexed 2P area-length volume was an independent predictor of LA thrombus (Table [4](#T4){ref-type="table"}). The same analysis with the parameters of CHA~2~DS~2~-VASc score reached similar results, with exception for dense SEC (Table [4](#T4){ref-type="table"}).

###### 

**Multivariate analysis including LA measurements and CHADS**~**2**~**/CHA**~**2**~**DS**~**2**~**-VASc parameters for prediction of TEE surrogate markers of stroke**

                       **TEE markers of stroke**                           **Independent predictors**           **OR**       **CI**~**95%**~    **p**
  ------------------------------------------------------------------- ------------------------------------ ---------------- ----------------- ---------
           **LA measurements + CHADS**~**2**~**parameters**                                                                                   
                           **LAA thrombus**                            • Indexed LA 2P Area-Length Volume       1.026         1.009 - 1.043     0.003
                                                                             • Previous stroke/TIA              4.080        1.647 -- 10.102    0.002
                              **LAA LFV**                                     • Indexed LA Area 4C              1.174        1.083 -- 1.272    \<0.001
                             **Dense SEC**                                    • Indexed LA Area 4C              1.090        1.018 -- 1.167     0.01
                              **LA ABN**                                      • Indexed LA Area 4C              1.114        1.037 -- 1.196     0.003
                                                                           • Congestive heart failure           2.022        1.109 -- 3.690     0.02
   **LA measurements + CHA**~**2**~**DS**~**2**~**-VASc parameters**                                                                          
                           **LAA thrombus**                            • Indexed LA 2P Area-Length Volume       1.028        1.010 -- 1.046     0.002
                                                                             • Previous stroke/TIA              4.071        1.568 -- 10.569    0.004
                              **LAA LFV**                                     • Indexed LA Area 4C              1.186        1.089 -- 1.291    \<0.001
                             **Dense SEC**                                   • Previous stroke/TIA              2.675        1.158 -- 6.180     0.02
                                                                           • Congestive heart failure           2.308        1.180 -- 4.514     0.02
                              **LA ABN**                                      • Indexed LA Area 4C              1.106        1.029 -- 1.190     0.006
                      • Congestive heart failure                                     2.097                  1.126 -- 3.907        0.02        

Legend: CI - confidence interval; LA -- left atrial; LAA -- left atrial appendage; LA ABN -- left atrial abnormality; LFV -- low flow velocities; OR -- odds ratio; p -- significance level; SEC -- spontaneous echocardiographic contrast; TEE -- transesophageal echocardiography; TIA -- transient ischemic attack; vel -- velocities; 4C -- 4-chamber; 2P -- biplane.

On multivariate analysis including the LA volumes and the CHADS~2~ score parameters, indexed 2P area-length volume was an independent predictor of LA thrombus, dense SEC and LA ABN; Indexed 1P area-length volume was independent predictor of LAA low flow velocities (Table [5](#T5){ref-type="table"}). The same analysis considering CHA~2~DS~2~-VASc score parameters reached similar results, with exception for dense SEC (Table [5](#T5){ref-type="table"}).

###### 

**Multivariate analysis including LA volume measurements and CHADS**~**2**~**/CHA**~**2**~**DS**~**2**~**-VASc parameters for prediction of TEE surrogate markers of stroke**

                    **TEE markers of stroke**                         **Independent predictors**           **OR**       **CI**~**95%**~    **p**
  -------------------------------------------------------------- ------------------------------------ ---------------- ----------------- ---------
           **LA Volumes + CHADS**~**2**~**parameters**                                                                                   
                         **LAA thrombus**                         • Indexed LA 2P Area-Length Volume       1.026        1.009 -- 1.043     0.003
                                                                        • Previous stroke/TIA              4.080        1.647 -- 10.102    0.002
                           **LAA LFV**                            • Indexed LA 1P Area-Length Volume       1.022        1.010 -- 1.034    \<0.001
                          **Dense SEC**                           • Indexed LA 2P Area-Length Volume       1.013          0.999-1.028      0.07
                    • Congestive heart failure                                  1.968                  1.024 -- 3.783        0.04        
                                                                        • Previous stroke/TIA              2.458        1.093 -- 5.530     0.03
                            **LA ABN**                            • Indexed LA 2P Area-Length Volume       1.021        1.006 -- 1.035     0.005
                                                                      • Congestive heart failure           2.065        1.134 -- 3.758     0.02
   **LA Volumes + CHA**~**2**~**DS**~**2**~**-VASc parameters**                                                                          
                         **LAA thrombus**                         • Indexed LA 2P Area-Length Volume       1.028        1.010 -- 1.046     0.002
                                                                        • Previous stroke/TIA              4.071        1.568 -- 10.569    0.004
                           **LAA LFV**                            • Indexed LA 1P Area-Length Volume       1.023        1.180 -- 1.037    \<0.001
                          **Dense SEC**                                 • Previous stroke/TIA              2.675        1.158 -- 6.180     0.02
                                                                      • Congestive heart failure           2.308        1.180 -- 4.514     0.02
                            **LA ABN**                            • Indexed LA 2P Area-Length Volume       1.019        1.005 -- 1.034     0.009
                    • Congestive heart failure                                  2.133                  1.147 -- 3.966        0.02        

Legend: CI - confidence interval; LA -- left atrial; LAA -- left atrial appendage; LA ABN -- left atrial abnormality; LFV -- low flow velocities; OR -- odds ratio; p -- significance level; SEC -- spontaneous echocardiographic contrast; TEE -- transesophageal echocardiography; TIA -- transient ischemic attack; vel -- velocities; 1P -- single-plane; 2P -- biplane.

A multivariate analysis taking into account LA areas and CHADS~2~ or CHA~2~DS~2~-VASc score parameters revealed indexed LA area 4C as an independent predictor of all TEE endpoints (Table [6](#T6){ref-type="table"}).

###### 

**Multivariate analysis including LA area measurements and CHADS**~**2**~**/CHA**~**2**~**DS**~**2**~**-VASc parameters for prediction of TEE surrogate markers of stroke**

                   **TEE markers of stroke**                      **Independent predictors**         **OR**       **CI**~**95%**~    **p**
  ------------------------------------------------------------ -------------------------------- ---------------- ----------------- ---------
           **LA Areas + CHADS**~**2**~**parameters**                                                                               
                        **LAA thrombus**                             • Indexed LA Area 4C            1.119         1.047 - 1.196     0.001
                                                                    • Previous stroke/TIA            3.977        1.987 -- 7.959    \<0.001
                          **LAA LFV**                                • Indexed LA Area 4C            1.141        1.075 -- 1.211    \<0.001
                         **Dense SEC**                               • Indexed LA Area 4C            1.136        1.078 -- 1.198    \<0.001
                           **LA ABN**                                • Indexed LA Area 4C            1.142        1.083 -- 1.204    \<0.001
                                                                  • Congestive heart failure         1.592        1.019 -- 2.487     0.04
   **LA Areas + CHA**~**2**~**DS**~**2**~**-VASc parameters**                                                                      
                        **LAA thrombus**                             • Indexed LA Area 4C            1.133        1.058 -- 1.213    \<0.001
                                                                    • Previous stroke/TIA            3.932        1.917 -- 8.069    \<0.001
                          **LAA LFV**                                • Indexed LA Area 4C            1.139         1.071-- 1.212    \<0.001
                         **Dense SEC**                               • Indexed LA Area 4C            1.125        1.065 -- 1.189    \<0.001
                                                                • Previous Vascular disease^a^       1.930        1.180 -- 3.154     0.009
                           **LA ABN**                                • Indexed LA Area 4C            1.147        1.086 -- 1.210    \<0.001
                 • Previous Vascular disease^a^                             1.581                1.010 -- 2.474        0.05        

Legend: CI - confidence interval; LA -- left atrial; LAA -- left atrial appendage; LA ABN -- left atrial abnormality; LFV -- low flow velocities; OR -- odds ratio; p -- significance level; SEC -- spontaneous echocardiographic contrast; TEE -- transesophageal echocardiography; TIA -- transient ischemic attack; vel -- velocities; 4C -- 4-chamber.

^a^Vascular disease is defined as having at least one of the following: myocardial infarctions, peripheral artery disease, and complex aortic plaque.

Inter- and intra-observer variability for the different LA size quantification methods, dense SEC and LAA thrombus is presented in Table [7](#T7){ref-type="table"}.

###### 

Inter- and intra-observer variability for the different LA quantification methods, dense spontaneous spontaneous echocardiographic contrast and left atrial appendage thrombus

       **Inter-observer variability**            **A vs B**              **A vs C**              **B vs C**
  ---------------------------------------- ----------------------- ----------------------- -----------------------
        LA AP Diameter (mean ± SD,%)             1.05 ± 0.19             1.04 ± 0.2              1.04 ± 0.18
          LA Area 4C (mean ± SD,%)               1.03 ± 0.23             1.04 ± 0.24             1.02 ± 0.21
     LA Ellipsoid Volume (mean ± SD,%)           1.12 ± 0.36             1.1 ± 0.36              1.08 ± 0.33
   LA 1P Area-Lenght Volume (mean ± SD,%)        1.09 ± 0.44             1.11 ± 0.47             1.06 ± 0.41
   LA 2P Area-Lenght Volume (mean ± SD,%)        1.05 ± 0.28             1.07 ± 0.28             1.03 ± 0.27
                 Dense SEC                  R = 0.797, p \< 0.001   R = 0.849, p \< 0.001   R = 0.841, p \< 0.001
                LAA Thrombus                R = 0.857, p \< 0.001     R =1, p \< 0.001      R = 0.857, p \< 0.001
       **Intra-observer variability**               **A**                   **B**                   **C**
        LA AP Diameter (mean ± SD,%)              1 ± 0.08                1 ± 0.08                1 ± 0.07
          LA Area 4C (mean ± SD,%)               1.01 ± 0.11             1.01 ± 0.09             1.01 ± 0.1
     LA Ellipsoid Volume (mean ± SD,%)           1.01 ± 0.1              01.01 ± 0.1             0.98 ± 0.11
   LA 1P Area-Lenght Volume (mean ± SD,%)        1.03 ± 0.24             1.02 ± 0.2              1.03 ± 0.22
   LA 2P Area-Lenght Volume (mean ± SD,%)        1.01 ± 0.15             1.01 ± 0.15             1.02 ± 0.14
                 Dense SEC                  R =0.901, p \< 0.001      R =1, p \< 0.001        R = 1, p \< 0.001
                LAA Thrombus                  R = 1, p \< 0.001       R = 1, p \< 0.001       R =1, p \< 0.001

Legend: LA -- left atrial; LAA -- left atrial appendage; SEC -- spontaneous echocardiographic contrast; 4C -- 4-chamber; 1P -- single-plane; 2P -- biplane.

A, B and C represent the three different echocardiographers.

For LA measurements are presented the results of Bland-Altman analysis, expressed as mean ± SD of the ratio of the measurements in comparison. For dense spontaneous spontaneous echocardiographic contrast and left atrial appendage thrombus are presented the variability is presented as a correlation.

Discussion
==========

Our results suggest that LA dilation is associated with an increase in the prevalence of TEE markers of increased thromboembolic risk in patients with AF, independently from recognized clinical risk factors. A stronger association was found for measurements indexed to body surface area, with the best discriminative ability obtained with indexed LA area 4C, indexed LA 1P area-length volume and indexed LA 2P area-length volume.

This is the first study to date evaluating and comparing the discriminative power of different methods for LA size measurement in the prediction of markers of left atrial stasis: LAA thrombus, dense SEC, LAA low flow velocities and LA ABN.

Predictors of left atrial stasis
--------------------------------

The presence of thrombus in the LAA, dense SEC, LAA low flow velocities and LA ABN are strongly associated with thromboembolism and adverse outcomes in patients with AF \[[@B22]-[@B24]\]. Accordingly, TEE has been recommended to evaluate the risk of thromboembolism previous to procedures such as cardioversion or catheter ablation \[[@B31],[@B32]\].

In this study population, the presence of LA ABN was associated with longer AF duration and higher thromboembolic risk assessed by CHADS~2~ and CHA~2~DS~2~-VASc scores, due to a higher prevalence of recognized thromboembolic risk factors such as older age, heart failure, vascular disease and systolic dysfunction (Table [2](#T2){ref-type="table"}). LA ABN was also associated with a larger left atrium, independently of the used method (Table [2](#T2){ref-type="table"}). On multivariate analysis, indexed LA area 4C and indexed 2P area-length volume were predictors of LA ABN (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). It is now established that LA enlargement is not considered part of the normal aging process, but related to underlying pathological processes such as systolic dysfunction, heart failure or vascular disease.

Left atrial size -- an underexplored marker of prothrombotic risk?
------------------------------------------------------------------

For all evaluated methods, a larger LA was associated to LA ABN (Table [2](#T2){ref-type="table"}). Also, most non-indexed and all indexed measurements showed moderate accuracy in the prediction of all thromboembolic risk markers assessed by TEE (Figure [2](#F2){ref-type="fig"}). Similar results were also found for identifying LAA low flow velocities or at least LAA low flow velocities or LAA thrombus in the subset of patients previously under oral anticoagulation. For predicting LAA thrombus in this subgroup, the results were not so consistent among the different LA measurements, however they may have been influenced by the small number of patients (n = 165) and the limited number of surrogate markers of stroke (LAA Thrombus: n = 21, low LAA flow velocities: n = 23, both n = 40) included in this sample.

On multivariate analysis, LA size was predictor of LA ABN, LAA thrombus, LAA low flow velocities and dense SEC independently from most thromboembolic risk factors used in CHADS~2~ and CHA~2~DS~2~-VASc scores (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). These results suggest that LA size may be used to predict stroke in patients with non-valvular AF and, eventually, improve thromboembolic risk stratification of these patients. In one study of 334 patients with AF undergoing transesophageal echocardiography, indexed LA volume was a significant predictor of LAA thrombus (OR 1.02, p = 0.02) and added incremental predictive value to left ventricle ejection fraction \[[@B33]\]. Another study demonstrated that LA area 4C associated to left ventricular ejection fraction could be used to identify LAA thrombus, LAA low flow velocities, dense SEC or LA ABN, and further refine the ability of CHADS~2~ and CHA~2~DS~2~-VASc scores to identify these TEE surrogate markers of stroke \[[@B34]\]. However, the discriminative capability of an isolated LA measurement to identify TEE surrogate markers of stroke has never been evaluated.

Due to the wide variety of LA size quantification methods, it seems important to identify the most suitable and accurate method for thromboembolic risk assessment. When assessing LA size it is crucial to index results to body surface area, as confirmed by the observed improvement in AUC with the different indexed methods in our sample.

The indexed measurements of LA area 4C, LA 1P and 2P area-length volumes stood out among all LA measurements for their moderate to high discriminatory power in the prediction of LAA thrombus, LAA low flow velocities, dense SEC and LA ABN (Figure [2](#F2){ref-type="fig"}), without significant differences between them (Table [3](#T3){ref-type="table"}). Indexed LA area 4C was an independent predictor of all TEE endpoints (Table [6](#T6){ref-type="table"}). Importantly, for dense SEC, LAA low flow velocities and LA ABN, this predictive ability was independent of other LA measurements (Table [4](#T4){ref-type="table"}). For LAA thrombus, indexed 2P area-length volume was a predictor of TEE surrogate markers of stroke, irrespectively of the other LA measurements (Table [4](#T4){ref-type="table"}). When considered separately from LA area 4C, the indexed LA area-length volumes also showed a good predictive ability for TEE surrogate markers of stroke (Table [5](#T5){ref-type="table"}).

LA enlargement is often asymmetrical, as enlargement in AP axis may be limited by the thoracic cavity, and it may also occur in medial-lateral or superior-inferior axes \[[@B11],[@B14]\]. Thus, LA AP diameter has been considered inaccurate, while LA areas or volumes assessed by TTE rely on fewer geometric assumptions. The 2P volume, using either the area-length or the discs formula, is the method currently recommended for LA size quantification \[[@B19]\]. In our study, this indexed method has also proved to be one of the most suitable to indicate the presence of TEE surrogate markers of stroke, yet single-plane area-length and area 4C methods showed a similar ability for this purpose.

Russo C and colleagues \[[@B13]\] evaluated single-plane and biplane methods for the assessment of LA volume against three-dimensional echocardiography in 527 participants of a community-based Cohort. They found strong correlations between single- and biplane LA volume measurements (r = 0.95, p \< 0.01), and single- (r = 0.93, p \< 0.01) and biplane (r = 0.93, p \< 0.01) area-length with three-dimensional volumes, although single-plane method had a suboptimal agreement for categorical classification. They suggested that single-plane method could simplify and expedite LA volume evaluation, but specific cut-off points should be developed for this method.

Similar results were also found for LA area 4C and single-plane area-length methods in the study of Badano LP and colleagues \[[@B15]\], who found an excellent correlation between LA area 4C (r = 0.94, p \< 0.0001), single-plane volume (r = 0.98, p \< 0.0001) and biplane volume (r = 0.99, p \< 0.0001) with volumes determined by three-dimensional echocardiography. They verified that the various methods of LA size quantification were not comparable, with a better agreement for single- and biplane volume methods, while LA area misled LA dilatation severity. They concluded that LA area inaccuracy was due mainly to inappropriate cut-off values than to the parameter itself. Furthermore, they suggested that the small additional accuracy obtained by using the biplane instead of the single-plane area--length method could allow the use of the single-plane method for routine clinical use \[[@B15]\]. Interestingly, reference ranges are also not available for indexed LA area 4C method in the last joint recommendations for chamber quantification \[[@B19]\].

In our study we found no significant differences when comparing indexed LA area 4C, LA 2P and 1P area-length volume for the discrimination of TEE markers of thromboembolic risk. This may be due to fact that differences between methods may be small and our sample may lack the necessary statistical power to demonstrate them. Further studies, sufficiently powered to assess this issue may be needed. However, at present moment there is no evidence suggesting that one should be preferred over the others for this specific aim.

Limitations
-----------

There are several limitations in this study that must be highlighted. First, this was a single-centre study, whose sample was not powered for enabling comparisons between some of the different methods used for assessing LA size.

Second, at the time of TEE, 40.6% of the study population was under oral anticoagulation, which may have had an impact in the prevalence of LA stasis markers. However, we believe this study cohort is representative of the general population of patients with AF and, as such, we decided not to exclude patients under oral anticoagulation. Moreover, some of these patients were not under therapeutic INR values and it is known that thrombi may arise even under therapeutic INR.

Conclusion
==========

LA enlargement, determined by indexed LA AP diameter, and indexed and non-indexed LA area 4C and volumes, is suitable to identify LAA thrombus, LAA low flow velocities, dense SEC and LA ABN in patients with non-valvular AF. The indexed measurements of LA area 4C, single- and biplane area-length volumes are the most accurate methods for this purpose, and may be used to stratify thromboembolic risk in these patients.
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